139 related articles for article (PubMed ID: 24500899)
21. Src activation is not necessary for transforming growth factor (TGF)-beta-mediated epithelial to mesenchymal transitions (EMT) in mammary epithelial cells. PP1 directly inhibits TGF-beta receptors I and II.
Maeda M; Shintani Y; Wheelock MJ; Johnson KR
J Biol Chem; 2006 Jan; 281(1):59-68. PubMed ID: 16267045
[TBL] [Abstract][Full Text] [Related]
22. Application of Rho-associated protein kinase (ROCK) inhibitor to human pluripotent stem cells.
Kurosawa H
J Biosci Bioeng; 2012 Dec; 114(6):577-81. PubMed ID: 22898436
[TBL] [Abstract][Full Text] [Related]
23. Inhibition of TGF-β Signaling in Tumor Cells by Small Molecule Src Family Kinase Inhibitors.
Bartscht T; Rosien B; Rades D; Kaufmann R; Biersack H; Lehnerta H; Ungefroren H
Anticancer Agents Med Chem; 2017; 17(10):1351-1356. PubMed ID: 28044939
[TBL] [Abstract][Full Text] [Related]
24. Pluripotent Stem Cell Differentiation Toward Functional Basal Stratified Epithelial Cells.
Soares E; Zhou H
Methods Mol Biol; 2022; 2454():297-304. PubMed ID: 32833130
[TBL] [Abstract][Full Text] [Related]
25. An Improved Two-Step Protocol for Trophoblast Differentiation of Human Pluripotent Stem Cells.
Horii M; Bui T; Touma O; Cho HY; Parast MM
Curr Protoc Stem Cell Biol; 2019 Sep; 50(1):e96. PubMed ID: 31479595
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of an NAD⁺ salvage pathway provides efficient and selective toxicity to human pluripotent stem cells.
Kropp EM; Oleson BJ; Broniowska KA; Bhattacharya S; Chadwick AC; Diers AR; Hu Q; Sahoo D; Hogg N; Boheler KR; Corbett JA; Gundry RL
Stem Cells Transl Med; 2015 May; 4(5):483-93. PubMed ID: 25834119
[TBL] [Abstract][Full Text] [Related]
27. A Src inhibitor regulates the cell cycle of human pluripotent stem cells and improves directed differentiation.
Chetty S; Engquist EN; Mehanna E; Lui KO; Tsankov AM; Melton DA
J Cell Biol; 2015 Sep; 210(7):1257-68. PubMed ID: 26416968
[TBL] [Abstract][Full Text] [Related]
28. Differentiation of Human Pluripotent Stem Cells to Cardiomyocytes Under Defined Conditions.
van den Berg CW; Elliott DA; Braam SR; Mummery CL; Davis RP
Methods Mol Biol; 2016; 1353():163-80. PubMed ID: 25626427
[TBL] [Abstract][Full Text] [Related]
29. Derivation of mesenchymal stromal cells from pluripotent stem cells through a neural crest lineage using small molecule compounds with defined media.
Fukuta M; Nakai Y; Kirino K; Nakagawa M; Sekiguchi K; Nagata S; Matsumoto Y; Yamamoto T; Umeda K; Heike T; Okumura N; Koizumi N; Sato T; Nakahata T; Saito M; Otsuka T; Kinoshita S; Ueno M; Ikeya M; Toguchida J
PLoS One; 2014; 9(12):e112291. PubMed ID: 25464501
[TBL] [Abstract][Full Text] [Related]
30. Impact of Feeding Strategies on the Scalable Expansion of Human Pluripotent Stem Cells in Single-Use Stirred Tank Bioreactors.
Kropp C; Kempf H; Halloin C; Robles-Diaz D; Franke A; Scheper T; Kinast K; Knorpp T; Joos TO; Haverich A; Martin U; Zweigerdt R; Olmer R
Stem Cells Transl Med; 2016 Oct; 5(10):1289-1301. PubMed ID: 27369897
[TBL] [Abstract][Full Text] [Related]
31. Monolayer Generation of Vascular Endothelial Cells from Human Pluripotent Stem Cells.
Christensen K; Roudnicky F; Burcin M; Patsch C
Methods Mol Biol; 2019; 1994():17-29. PubMed ID: 31124101
[TBL] [Abstract][Full Text] [Related]
32. Facile engineering of xeno-free microcarriers for the scalable cultivation of human pluripotent stem cells in stirred suspension.
Fan Y; Hsiung M; Cheng C; Tzanakakis ES
Tissue Eng Part A; 2014 Feb; 20(3-4):588-99. PubMed ID: 24098972
[TBL] [Abstract][Full Text] [Related]
33. Efficient derivation of human neuronal progenitors and neurons from pluripotent human embryonic stem cells with small molecule induction.
Parsons XH; Teng YD; Parsons JF; Snyder EY; Smotrich DB; Moore DA
J Vis Exp; 2011 Oct; (56):e3273. PubMed ID: 22064669
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of ROCK-myosin II signaling pathway enables culturing of human pluripotent stem cells on microcarriers without extracellular matrix coating.
Chen AK; Chen X; Lim YM; Reuveny S; Oh SK
Tissue Eng Part C Methods; 2014 Mar; 20(3):227-38. PubMed ID: 23777438
[TBL] [Abstract][Full Text] [Related]
35. Improving the safety of human pluripotent stem cell therapies using genome-edited orthogonal safeguards.
Martin RM; Fowler JL; Cromer MK; Lesch BJ; Ponce E; Uchida N; Nishimura T; Porteus MH; Loh KM
Nat Commun; 2020 Jun; 11(1):2713. PubMed ID: 32483127
[TBL] [Abstract][Full Text] [Related]
36. Bioprocess development for mass production of size-controlled human pluripotent stem cell aggregates in stirred suspension bioreactor.
Abbasalizadeh S; Larijani MR; Samadian A; Baharvand H
Tissue Eng Part C Methods; 2012 Nov; 18(11):831-51. PubMed ID: 22559864
[TBL] [Abstract][Full Text] [Related]
37. A Newly Defined and Xeno-Free Culture Medium Supports Every-Other-Day Medium Replacement in the Generation and Long-Term Cultivation of Human Pluripotent Stem Cells.
Ahmadian Baghbaderani B; Tian X; Scotty Cadet J; Shah K; Walde A; Tran H; Kovarcik DP; Clarke D; Fellner T
PLoS One; 2016; 11(9):e0161229. PubMed ID: 27606941
[TBL] [Abstract][Full Text] [Related]
38. Small-Molecule-Directed Hepatocyte-Like Cell Differentiation of Human Pluripotent Stem Cells.
Mathapati S; Siller R; Impellizzeri AA; Lycke M; Vegheim K; Almaas R; Sullivan GJ
Curr Protoc Stem Cell Biol; 2016 Aug; 38():1G.6.1-1G.6.18. PubMed ID: 27532814
[TBL] [Abstract][Full Text] [Related]
39. Directed Endothelial Progenitor Differentiation from Human Pluripotent Stem Cells Via Wnt Activation Under Defined Conditions.
Bao X; Lian X; Palecek SP
Methods Mol Biol; 2016; 1481():183-96. PubMed ID: 27590162
[TBL] [Abstract][Full Text] [Related]
40. Normal timing of oligodendrocyte development from genetically engineered, lineage-selectable mouse ES cells.
Billon N; Jolicoeur C; Ying QL; Smith A; Raff M
J Cell Sci; 2002 Sep; 115(Pt 18):3657-65. PubMed ID: 12186951
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
